Attenuation of coxsackievirus B3 by VP2 mutation and its application as a vaccine against virus-induced myocarditis and pancreatitis

Jung Hyun Park; Dae Sun Kim; Young Joo Cho; Yeon Jung Kim; Soo Young Jeong; Seung Min Lee; Seong Joo Cho; Cheol Won Yun; Inho Jo; Jae Hwan Nam

doi:10.1016/j.vaccine.2009.01.008

Attenuation of coxsackievirus B3 by VP2 mutation and its application as a vaccine against virus-induced myocarditis and pancreatitis

Jung Hyun Park, Dae Sun Kim, Young Joo Cho, Yeon Jung Kim, Soo Young Jeong, Seung Min Lee, Seong Joo Cho, Cheol Won Yun, Inho Jo, Jae Hwan Nam

Research output: Contribution to journal › Article › peer-review

28 Citations (Scopus)

Abstract

Coxsackievirus B3 (CVB3) is a common agent of viral myocarditis, a major cause of sudden cardiac death, and ultimately dilated cardiomyopathy. However, there is no vaccine in clinical use. In this study, we identified the conserved amino acid sequences in the C-terminal region of the VP2 of the coxsackievirus B group and some echoviruses. The mutant virus, YYFF, with phenylalanines substituted for two tyrosines in these conserved sequences was highly attenuated in vivo and could induce a high neutralizing antibody titer and a cytotoxic T-lymphocyte response against CVB3. Thereby, mutant-virus-immunized mice showed a 100% survival rate and protection against inflammation of the heart and pancreas after lethal dose challenge. Thus, this mutant virus is a good candidate for an attenuated CVB3 vaccine.

Original language	English
Pages (from-to)	1974-1983
Number of pages	10
Journal	Vaccine
Volume	27
Issue number	13
DOIs	https://doi.org/10.1016/j.vaccine.2009.01.008
Publication status	Published - 2009 Mar 18

Bibliographical note

Funding Information:
We are grateful to Eun-Kyung Kim for the statistical analysis and to Dr. Randal Johnston for critical reading and editing. This work was supported by grants from the Korea Health 21 R&D project, the Ministry of Health & Welfare, Republic of Korea (A050768), the KNIH, the KFDA, the Gyeonggi Regional Research Center (GRRC) of the Catholic University of Korea, and the Research Fund, 2008 of the Catholic University of Korea as well as the Ministry of Knowledge Economy (MKE) and Korea Industrial Technology Foundation (KOTEF) through the Human Resource Training Project for Strategic Technology

Keywords

Attenuated vaccine
Coxsackievirus
VP2

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2009.01.008

Cite this

@article{f97b62e739d946158c900e89dc5732d8,

title = "Attenuation of coxsackievirus B3 by VP2 mutation and its application as a vaccine against virus-induced myocarditis and pancreatitis",

abstract = "Coxsackievirus B3 (CVB3) is a common agent of viral myocarditis, a major cause of sudden cardiac death, and ultimately dilated cardiomyopathy. However, there is no vaccine in clinical use. In this study, we identified the conserved amino acid sequences in the C-terminal region of the VP2 of the coxsackievirus B group and some echoviruses. The mutant virus, YYFF, with phenylalanines substituted for two tyrosines in these conserved sequences was highly attenuated in vivo and could induce a high neutralizing antibody titer and a cytotoxic T-lymphocyte response against CVB3. Thereby, mutant-virus-immunized mice showed a 100% survival rate and protection against inflammation of the heart and pancreas after lethal dose challenge. Thus, this mutant virus is a good candidate for an attenuated CVB3 vaccine.",

keywords = "Attenuated vaccine, Coxsackievirus, VP2",

author = "Park, {Jung Hyun} and Kim, {Dae Sun} and Cho, {Young Joo} and Kim, {Yeon Jung} and Jeong, {Soo Young} and Lee, {Seung Min} and Cho, {Seong Joo} and Yun, {Cheol Won} and Inho Jo and Nam, {Jae Hwan}",

note = "Funding Information: We are grateful to Eun-Kyung Kim for the statistical analysis and to Dr. Randal Johnston for critical reading and editing. This work was supported by grants from the Korea Health 21 R&D project, the Ministry of Health & Welfare, Republic of Korea (A050768), the KNIH, the KFDA, the Gyeonggi Regional Research Center (GRRC) of the Catholic University of Korea, and the Research Fund, 2008 of the Catholic University of Korea as well as the Ministry of Knowledge Economy (MKE) and Korea Industrial Technology Foundation (KOTEF) through the Human Resource Training Project for Strategic Technology",

year = "2009",

month = mar,

day = "18",

doi = "10.1016/j.vaccine.2009.01.008",

language = "English",

volume = "27",

pages = "1974--1983",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "13",

}

TY - JOUR

T1 - Attenuation of coxsackievirus B3 by VP2 mutation and its application as a vaccine against virus-induced myocarditis and pancreatitis

AU - Park, Jung Hyun

AU - Kim, Dae Sun

AU - Cho, Young Joo

AU - Kim, Yeon Jung

AU - Jeong, Soo Young

AU - Lee, Seung Min

AU - Cho, Seong Joo

AU - Yun, Cheol Won

AU - Jo, Inho

AU - Nam, Jae Hwan

N1 - Funding Information: We are grateful to Eun-Kyung Kim for the statistical analysis and to Dr. Randal Johnston for critical reading and editing. This work was supported by grants from the Korea Health 21 R&D project, the Ministry of Health & Welfare, Republic of Korea (A050768), the KNIH, the KFDA, the Gyeonggi Regional Research Center (GRRC) of the Catholic University of Korea, and the Research Fund, 2008 of the Catholic University of Korea as well as the Ministry of Knowledge Economy (MKE) and Korea Industrial Technology Foundation (KOTEF) through the Human Resource Training Project for Strategic Technology

PY - 2009/3/18

Y1 - 2009/3/18

N2 - Coxsackievirus B3 (CVB3) is a common agent of viral myocarditis, a major cause of sudden cardiac death, and ultimately dilated cardiomyopathy. However, there is no vaccine in clinical use. In this study, we identified the conserved amino acid sequences in the C-terminal region of the VP2 of the coxsackievirus B group and some echoviruses. The mutant virus, YYFF, with phenylalanines substituted for two tyrosines in these conserved sequences was highly attenuated in vivo and could induce a high neutralizing antibody titer and a cytotoxic T-lymphocyte response against CVB3. Thereby, mutant-virus-immunized mice showed a 100% survival rate and protection against inflammation of the heart and pancreas after lethal dose challenge. Thus, this mutant virus is a good candidate for an attenuated CVB3 vaccine.

AB - Coxsackievirus B3 (CVB3) is a common agent of viral myocarditis, a major cause of sudden cardiac death, and ultimately dilated cardiomyopathy. However, there is no vaccine in clinical use. In this study, we identified the conserved amino acid sequences in the C-terminal region of the VP2 of the coxsackievirus B group and some echoviruses. The mutant virus, YYFF, with phenylalanines substituted for two tyrosines in these conserved sequences was highly attenuated in vivo and could induce a high neutralizing antibody titer and a cytotoxic T-lymphocyte response against CVB3. Thereby, mutant-virus-immunized mice showed a 100% survival rate and protection against inflammation of the heart and pancreas after lethal dose challenge. Thus, this mutant virus is a good candidate for an attenuated CVB3 vaccine.

KW - Attenuated vaccine

KW - Coxsackievirus

KW - VP2

UR - http://www.scopus.com/inward/record.url?scp=61349151123&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2009.01.008

DO - 10.1016/j.vaccine.2009.01.008

M3 - Article

C2 - 19168108

AN - SCOPUS:61349151123

SN - 0264-410X

VL - 27

SP - 1974

EP - 1983

JO - Vaccine

JF - Vaccine

IS - 13

ER -

Attenuation of coxsackievirus B3 by VP2 mutation and its application as a vaccine against virus-induced myocarditis and pancreatitis

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this